Key result
Anti-FXa assays incorporating low molecular weight dextran sulfate and utilizing CTAD anticoagulant optimize the accurate measurement of all in-vivo heparin activity.
Why the study?
External quality assessment surveys still report high inter-assay variability for anti-FXa assays despite WHO international standards, driven by assay formulation, calibrators, and automation parameters.
Does the addition of dextran sulfate and use of CTAD anticoagulant improve the accuracy of anti-FXa assays for measuring heparin activity?
Population
Plasmas from patients treated with UFH or LMWH
Comparison
Assay formulations with vs without dextran sulfate and citrate vs CTAD anticoagulants
Design
Review with comparative assay performance evaluation
Authors
Loading...
May refine heparin monitoring in labs; hypothesis-generating and requires prospective validation before any practice change.
Does the addition of dextran sulfate and use of CTAD anticoagulant improve the accuracy of anti-FXa assays for measuring heparin activity?
Optimizing anti-FXa assays with dextran sulfate and CTAD anticoagulant improves the accuracy of heparin monitoring by mobilizing all drug present in blood circulation.
Amiral et al. (2021) conducted a review in Heparin therapy monitoring. Anti-FXa assays with dextran sulfate and CTAD anticoagulant vs. Assays without dextran sulfate or using citrate was evaluated on Heparin measurement accuracy. Anti-FXa assays incorporating low molecular weight dextran sulfate and utilizing CTAD anticoagulant optimize the accurate measurement of all in-vivo heparin activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: